Abbott Receives CE Mark for Next-Generation Mitraclip Heart Valve Repair Device to Treat Mitral

Originally posted on Abbott.com

– CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology

– MitraClip is a first-of-its-kind transcatheter mitral valve therapy, now on its fourth generation, improving further on MitraClip’s history as a safe and effective treatment option

 

Abbott (NYSE: ABT) announced it has received CE Mark for its fourth-generation MitraClip™ Transcatheter Mitral Valve Repair System, the leading minimally invasive mitral valve repair device in the world. Known as MitraClip G4, the device is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical option for the treatment of mitral regurgitation (MR), or a leaky heart valve. The device is already approved for use in the U.S.

The MitraClip G4 system provides physicians in Europe with enhancements to MitraClip’s first-of-its-kind clip-based technology, building upon the device’s proven delivery system. In addition to offering advanced steering during implantation, the new delivery system offers four clip sizes, including two wider clips, for doctors to have a greater variety of treatment options that can be tailored to a patients’ unique mitral valve anatomy.1 The newest-generation device also offers independently controlled grippers, if needed, that allow physicians to grasp one or both mitral valve leaflets at a time during the MitraClip procedure.

MR is one of the most common heart conditions, affecting one in 10 adults age 75 and older.2,3 Patients with this progressive condition have a mitral valve that does not close completely, allowing blood to flow backward into the left atrium of the heart instead of forwards (out of the heart) and to the rest of the body. While medication can help people manage the symptoms of MR, it does not treat the leaky valve itself. Prior to MitraClip, open-heart surgery was the standard treatment for MR, however, not all patients are eligible or appropriate for open-heart surgery due to the potential risk of complications stemming from comorbidities, advanced age or other issues.

MitraClip is a first-of-its-kind minimally invasive transcatheter mitral valve repair (TMVr) therapy that can be a life-saving treatment option for select patients with primary or secondary MR.4 The small clip-based device is delivered to the heart through a vein in the leg and clips portions of the leaflets, or flaps, of the mitral valve together to reduce the backflow of blood. Once in place, MitraClip restores the proper functioning of the mitral valve and the heart’s ability to pump oxygenated blood more efficiently.

“Despite being consistently recognized as a problem in patients around the world, MR cannot be treated through the conventional method of open-heart mitral valve surgery in more than half of the people who have this condition,” said Ralph Stephan Von Bardeleben, head of the Heart Valve Center Mainz, Universitätsmedizin Mainz, Germany, who treated the first MitraClip G4 patients in the EU. “The newest MitraClip therapy offers physicians a reliable option when surgical treatment of MR isn’t possible or appropriate, and MitraClip G4’s enhancements allow further customization of the therapy to tailor treatment to individual patient needs.”

MitraClip is backed by more than 16 years of clinical experience with proven safety, survival and durable clinical outcomes. Data presented at PCR e-Course this year from a real-world clinical study of over 1,000 MitraClip patients showed a high implant success rate (99%) and demonstrated MR reduction to the level of none or trace in patients with either primary MR (to ≤1+ in 87.1%) or secondary MR (to ≤1+ in 90.1%) at 30 days. This recent data confirms MitraClip’s best-in-class MR reduction to date1 and adds to a body of evidence that demonstrates significant impact for patients, including improved clinical outcomes and quality of life.

“An enduring measure of our mission to help people live better lives through better health is our success in advancing new standards of care for the treatment of structural heart diseases,” said Michael Dale, senior vice president of Abbott’s structural heart business. “This CE Mark, along with other recent approvals and advancements for our MitraClip device, underscores the need for MitraClip’s innovative therapy – which has become a preferred choice for the treatment of mitral regurgitation around the world.”

The MitraClip system has been commercially available in the U.S. since 2013 and in Europe since 2008. Recent regulatory milestones for the device include the first-ever commercial introduction of MitraClip therapy to China and approval in Japan for the fourth generation of MitraClip, both in June of 2020. These milestones are of critical importance for the Asia-Pacific region where many people suffer from MR but may not have had a treatment option available to them. Since its initial approval, more than 100,000 people have been treated with MitraClip in all major regions around the world.

For U.S. important safety information on MitraClip™ visit http://abbo.tt/MitraClipG4ISI.

Latest News

San Francisco's Golden Gate Bridge

San Francisco Declares War on Racism; People 55 and Older Face Historic Levels of Unemployment; and More.

San Francisco begins a citywide war on racism and discrimination. Known as the birthplace of the “Summer of Love” and the counterculture movement of the 1960s, San Francisco has long stood as a bastion of individuality and inclusion. And now the city is continuing that fight with the launch of…

portrait of Abraham Lincoln

Was Abraham Lincoln a Racist?

Former Vice President Joe Biden’s mention of Abraham Lincoln’s name during the third presidential debate on Thursday, Oct. 22, was one of the most memorable exchanges in the final presidential debate of 2020. It also caused Lincoln to become a trending topic over much of social media in the hours…

AOC celebrates a victory in Among Us during her Twitch stream

AOC Livestreamed ‘Among Us’ on Twitch to Encourage Everyone (but Particularly Young People) to Vote

New York congresswoman Alexandria Ocasio-Cortez (AOC) is stepping up Democratic efforts to make sure young voters are prepared when heading to the polls on Election Day, especially in light of COVID-19. On Oct. 21, 2020, AOC livestreamed on Twitch to engage with the younger demographic that frequents the video game-centric…

Black Lives Matter face mask for preventing spread of COVID-19

BLM T-shirts and Trump Masks Cause Uproar at Early Polling Locations; New Credit Cards Allow Trans Individuals to Use Preferred Name; and More

BLM T-shirts and Trump masks cause uproar at early polling locations. Voters’ choice of clothing when heading to the polls in Florida and Tennessee has begun making headlines across the country. The Washington Post reported that Miami police officer Daniel Ubeda has come under fire for wearing a Trump-endorsing face…

Close-up image of COVID-19 virus

Black and Latinx Individuals Increasingly Worried About Impact of COVID-19 on Career; Potential Spike in New Disabilities Due to Pandemic; and More

More than 50% of Blacks and Latinx individuals significantly worried about finances and career prospects due to pandemic. COVID-19 continues to be top of mind for most of the country, especially as cases appear to be worsening in our current third wave of the illness. But a new survey of…

Rep. Jahana Hayes (D-Conn.)

Rep. Jahana Hayes Attacked in Racist Campaign Town Hall; 1 in 4 Americans Unemployed According to New Data from Axios; and More

Racist trolls interrupt Zoom town hall hosted by Jahana Hayes, Connecticut’s first Black congresswoman. “I am not OK,” wrote Rep. Jahana Hayes (D-Conn.) in a moving post describing a violent attack that took place at one of her recent campaign events. Ten minutes into the Zoom town hall for one…